$PVCT
PROVECTUS BIOPHARMACEUTICALS, INC. Stock $pvct

$pvct Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000149315222031108 Filed on November 09, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q3
Revenue	$164.8K	$314.9K	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$309.5K	$334.0K	$306.8K
YoY Change	-15.96%	8.88%	-11.29%
% of Gross Profit
Research & Development	$319.4K	$580.4K	$606.5K
YoY Change	-56.8%	-4.3%	-8.85%
% of Gross Profit
Depreciation & Amortization	$2.040K	$2.820K	$3.220K
YoY Change	-36.65%	-12.42%	-5.85%
% of Gross Profit
Operating Expenses	$630.9K	$981.1K	$916.5K
YoY Change	-43.2%	7.05%	-9.67%
Operating Profit		-$666.2K	-$1.047M
YoY Change		-36.39%
Interest Expense	-$48.48K	-$46.44K	-$3.560K
YoY Change	199.63%	1204.49%	-99.23%
% of Operating Profit
Other Income/Expense, Net	-$670.00	-$47.08K	-$510.00
YoY Change	109.38%	9130.98%
Pretax Income	-$732.7K	-$713.3K	-$1.051M
YoY Change	-40.86%	-32.15%	-32.8%
Income Tax	$0.00
% Of Pretax Income
Net Earnings	-$732.7K	-$713.3K	-$1.051M
YoY Change	-40.86%	-32.15%	-32.8%
Net Earnings / Revenue	-444.46%	-226.51%
Basic Earnings Per Share		$0.00	$0.00
Diluted Earnings Per Share	$0.00	-$1.700K	-$2.564K
COMMON SHARES
Basic Shares Outstanding	419.5M shares	419.5M shares	410.0M shares
Diluted Shares Outstanding		419.5M shares

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$21.61K	$67.03K	$254.1K
YoY Change	-96.84%	-73.62%	-74.24%
Cash & Equivalents	$21.61K	$67.03K	$254.1K
Short-Term Investments
Other Short-Term Assets	$1.877M	$1.832M	$251.1K
YoY Change	-31.83%	629.49%	51.99%
Inventory
Prepaid Expenses	$467.1K	$187.5K
Receivables			$1.350K
Other Receivables			$0.00
Total Short-Term Assets	$1.899M	$1.899M	$506.5K
YoY Change	-44.82%	274.97%	-56.24%
LONG-TERM ASSETS
Property, Plant & Equipment	$20.94K	$22.98K	$93.79K
YoY Change	-34.22%	-75.5%	-49.88%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$138.1K	$151.0K	$93.79K
YoY Change	93.37%	61.04%	-49.88%
TOTAL ASSETS
Total Short-Term Assets	$1.899M	$1.899M	$506.5K
Total Long-Term Assets	$138.1K	$151.0K	$93.79K
Total Assets	$2.037M	$2.050M	$600.3K
YoY Change	-42.01%	241.55%	-55.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.094M	$1.941M	$1.260M
YoY Change	62.67%	54.12%	18.31%
Accrued Expenses	$2.520M	$2.615M	$1.871M
YoY Change	22.06%	39.75%	-66.58%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$710.0K	$200.0K
YoY Change	-100.0%	255.0%	-97.05%
Long-Term Debt Due	$2.067M	$1.882M	$68.39K
YoY Change	37.94%	2652.07%	-99.59%
Total Short-Term Liabilities	$8.192M	$8.824M	$3.549M
YoY Change	6.39%	148.63%	-88.15%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$73.38K	$85.02K	$0.00
YoY Change			-100.0%
Total Long-Term Liabilities	$73.38K	$85.02K	$0.00
YoY Change			-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$8.192M	$8.824M	$3.549M
Total Long-Term Liabilities	$73.38K	$85.02K	$0.00
Total Liabilities	$8.266M	$8.909M	$3.549M
YoY Change	7.34%	151.03%	-88.19%
SHAREHOLDERS EQUITY
Retained Earnings	-$249.6M	-$248.9M
YoY Change	1.44%
Common Stock	$419.5K	$419.5K
YoY Change	0.01%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$6.229M	-$6.859M	-$2.949M
YoY Change
Total Liabilities & Shareholders Equity	$2.037M	$2.050M	$600.3K
YoY Change	-42.01%	241.55%	-55.36%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q3
OPERATING ACTIVITIES
Net Income	-$732.7K	-$713.3K	-$1.051M
YoY Change	-40.86%	-32.15%	-32.8%
Depreciation, Depletion And Amortization	$2.040K	$2.820K	$3.220K
YoY Change	-36.65%	-12.42%	-5.85%
Cash From Operating Activities	-$754.8K	-$816.6K	-$730.3K
YoY Change	-146.54%	11.82%	-49.43%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	474.2K	496.9K	937.9K
YoY Change	-61.48%	-47.03%	-1.31%
NET CHANGE
Cash From Operating Activities	-754.8K	-816.6K	-730.3K
Cash From Investing Activities
Cash From Financing Activities	474.2K	496.9K	937.9K
Net Change In Cash	-280.6K	-319.7K	207.7K
YoY Change	-109.84%	-253.96%	-142.06%
FREE CASH FLOW
Cash From Operating Activities	-$754.8K	-$816.6K	-$730.3K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Interest Paid Net InterestPaidNet		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	PVCT	Deposit Applied To Equity Issuances DepositAppliedToEquityIssuances		usd
	PVCT	Conversion Of Nonamended Notes To Preferred Stock ConversionOfNonamendedNotesToPreferredStock		usd
	PVCT	Conversion Of Amended Notes And Notes To Preferred Stock One ConversionOfAmendedNotesAndNotesToPreferredStockOne		usd
	PVCT	Conversion Of Series D1 Preferred Stock To Common Stock ConversionOfSeriesD1PreferredStockToCommonStock		usd
	PVCT	Rightofuse Asset For Lease Liability RightofuseAssetForLeaseLiability		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Central Index Key EntityCentralIndexKey	0000315545
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
CY2022Q3	PVCT	Deposit For Purchase Of Preferred Stock DepositForPurchaseOfPreferredStock		usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
CY2022Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2021Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2021Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices		usd
CY2021Q3	PVCT	Adjustments To Additional Paid In Capital Conversion Of Series B Preferred Stock To Common Stock AdjustmentsToAdditionalPaidInCapitalConversionOfSeriesBPreferredStockToCommonStock		usd
CY2021Q3	PVCT	Adjustments To Additional Paid In Capital Conversion Of Series D1 Preferred Stock To Common Stock AdjustmentsToAdditionalPaidInCapitalConversionOfSeriesD1PreferredStockToCommonStock		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue		usd
	us-gaap	Payments For Proceeds From Deposit On Loan PaymentsForProceedsFromDepositOnLoan		usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2021Q3	us-gaap	Restricted Cash RestrictedCash		usd
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
CY2022Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
	PVCT	Weighted Average Exercise Price Granted WeightedAverageExercisePriceGranted
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised		shares
CY2022Q3	us-gaap	Notes Payable To Bank Current NotesPayableToBankCurrent	72135	usd
	PVCT	Weighted Average Exercise Price Exercised WeightedAverageExercisePriceExercised
CY2021Q4	PVCT	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue		usd
CY2022Q3	PVCT	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue		usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Entity File Number EntityFileNumber	001-36457
	dei	Entity Registrant Name EntityRegistrantName	PROVECTUS BIOPHARMACEUTICALS, INC.
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	90-0031917
	dei	Entity Address Address Line1 EntityAddressAddressLine1	800 S Gay Street
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 1610
	dei	Entity Address City Or Town EntityAddressCityOrTown	Knoxville
	dei	Entity Address State Or Province EntityAddressStateOrProvince	TN
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	37929
	dei	City Area Code CityAreaCode	866
	dei	Local Phone Number LocalPhoneNumber	594-5999
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	419547119	shares
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	67030	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	682984	usd
CY2022Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	1644321	usd
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	2423958	usd
CY2022Q3	us-gaap	Receivables Net Current ReceivablesNetCurrent	564	usd
CY2021Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	5107	usd
CY2022Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	187500	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	329908	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	1899415	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	3441957	usd
CY2022Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	100035	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	91178	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	22979	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	31836	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	128059	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	39563	usd
CY2022Q3	us-gaap	Assets Assets	2050453	usd
CY2021Q4	us-gaap	Assets Assets	3513356	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1941315	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1287459	usd
CY2021Q4	PVCT	Deposit For Purchase Of Preferred Stock DepositForPurchaseOfPreferredStock	150000	usd
CY2022Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1675795	usd
CY2021Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	2500000	usd
CY2022Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2444224	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2002486	usd
CY2022Q3	us-gaap	Interest Payable Current InterestPayableCurrent	104589	usd
CY2021Q4	us-gaap	Interest Payable Current InterestPayableCurrent	10578	usd
CY2022Q3	PVCT	Interest Payable To Related Parties Current InterestPayableToRelatedPartiesCurrent	22569	usd
CY2021Q4	PVCT	Interest Payable To Related Parties Current InterestPayableToRelatedPartiesCurrent	6044	usd
CY2021Q4	us-gaap	Notes Payable To Bank Current NotesPayableToBankCurrent	238452	usd
CY2022Q3	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	1810000	usd
CY2021Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	1260000	usd
CY2022Q3	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	710000	usd
CY2021Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	200000	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	43377	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	45617	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	8824004	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7700636	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	85019	usd
CY2022Q3	us-gaap	Liabilities Liabilities	8909023	usd
CY2021Q4	us-gaap	Liabilities Liabilities	7700636	usd
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	419497119	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	419497119	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	419447119	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	419447119	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	419497	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	419447	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	241593029	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	241440106	usd
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-36752	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-34467	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-248855988	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-246033958	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-6858570	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-4187280	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2050453	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3513356	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	314890	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	824205	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	580390	usd
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	608653	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2068154	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1866776	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	400689	usd
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	438578	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1500278	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1583148	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	981079	usd
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	1047231	usd
	us-gaap	Operating Expenses OperatingExpenses	3568432	usd
	us-gaap	Operating Expenses OperatingExpenses	3449924	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-666189	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1047231	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2744227	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3449924	usd
CY2022Q3	PVCT	Research And Development Tax Credit ResearchAndDevelopmentTaxCredit	-638	usd
CY2021Q3	PVCT	Research And Development Tax Credit ResearchAndDevelopmentTaxCredit	-507	usd
	PVCT	Research And Development Tax Credit ResearchAndDevelopmentTaxCredit	37621	usd
	PVCT	Research And Development Tax Credit ResearchAndDevelopmentTaxCredit	31637	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	63094	usd
CY2022Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-46440	usd
CY2021Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-3521	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-115424	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-945607	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-47078	usd
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4028	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-77803	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-850876	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-713267	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-1051259	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2822030	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4300800	usd
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	419489239	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	409961614	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	419461313	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	405286784	shares
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-713267	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-1051259	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2822030	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4300800	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	-1241	usd
CY2021Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	-193	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	-2285	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	-477	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-714508	usd
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1051452	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2824315	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4301277	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-4187280	usd
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	150000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-1030922	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-716	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-5068918	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-1077841	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-328	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-6147087	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	3025	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-713267	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1241	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-6858570	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-30206357	usd
CY2021Q1	PVCT	Stock Issued During Period Value Issued Upon Exercise Of Warrants StockIssuedDuringPeriodValueIssuedUponExerciseOfWarrants	239850	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	19750	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-1669950	usd
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	837	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-31615870	usd
CY2021Q2	PVCT	Stock Issued During Period Value Issued Upon Exercise Of Warrants StockIssuedDuringPeriodValueIssuedUponExerciseOfWarrants	10660	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1675	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	488	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	3541222	usd
CY2021Q2	PVCT	Stock Issued During Period Value Conversion Of Convertible Securities One StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesOne	27031858	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-1579591	usd
CY2021Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1121	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-2610679	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-2610679	usd
CY2021Q3	PVCT	Stock Issued During Period Value Issued Upon Exercise Of Warrants StockIssuedDuringPeriodValueIssuedUponExerciseOfWarrants	711713	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1775	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-1051259	usd
CY2021Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-193	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	-2948643	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	-2948643	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2822030	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4300800	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	3025	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	23688	usd
	PVCT	Noncash Lease Expense NoncashLeaseExpense	41947	usd
	PVCT	Noncash Lease Expense NoncashLeaseExpense	62085	usd
	us-gaap	Depreciation Depreciation	8857	usd
	us-gaap	Depreciation Depreciation	9648	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	63094	usd
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-4351	usd
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-2448	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-142129	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-145639	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	654017	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	302978	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-824205	usd
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	442355	usd
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	306116	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-47664	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-66246	usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	110536	usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	942257	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2286682	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2635281	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	550000	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	1700000	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	510000	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	200000	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	166317	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	219172	usd
	us-gaap	Payments For Proceeds From Deposit On Loan PaymentsForProceedsFromDepositOnLoan	-150000	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	962223	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	893683	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2793051	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-2592	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-918	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1395591	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	156852	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3106942	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	97231	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1711351	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	254083	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	67030	usd
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	254083	usd
CY2022Q3	us-gaap	Restricted Cash RestrictedCash	1644321	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1711351	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	254083	usd
	PVCT	Purchase Of Insurance Policies Financed By Shortterm Note Payable PurchaseOfInsurancePoliciesFinancedByShorttermNotePayable	-57146	usd
	PVCT	Purchase Of Insurance Policies Financed By Shortterm Note Payable PurchaseOfInsurancePoliciesFinancedByShorttermNotePayable	-282667	usd
	PVCT	Deposit Applied To Equity Issuances DepositAppliedToEquityIssuances	-150000	usd
	PVCT	Conversion Of Nonamended Notes To Preferred Stock ConversionOfNonamendedNotesToPreferredStock	3541222	usd
	PVCT	Conversion Of Amended Notes And Notes To Preferred Stock One ConversionOfAmendedNotesAndNotesToPreferredStockOne	27031858	usd
	PVCT	Conversion Of Series D1 Preferred Stock To Common Stock ConversionOfSeriesD1PreferredStockToCommonStock	222	usd
	PVCT	Rightofuse Asset For Lease Liability RightofuseAssetForLeaseLiability	130422	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_809_eus-gaap--NatureOfOperations_z1ZDZUJSUA75" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1. <span id="xdx_826_zeqERWhFDeL5">Business Organization, Nature of Operations and Basis of Presentation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Provectus Biopharmaceuticals, Inc., a Delaware corporation (together with its subsidiaries, “Provectus” or “the Company”), is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases that are based on a class of synthetic small molecule immuno-modulators called halogenated xanthenes (“HXs”). Our lead molecule is named rose bengal sodium (“RBS”).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company’s proprietary, patented, pharmaceutical-grade RBS is the active pharmaceutical ingredient in the drug product candidates of our current clinical development programs and the preclinical formulations of our current drug discovery programs. Importantly, our pharmaceutical-grade RBS displays different therapeutic effects at different concentrations and can be formulated for delivery by different routes of administration,</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company believes that RBS targets disease in a bifunctional manner. First, direct contact may lead to cell death or repair depending on the disease being treated and the concentration of the RBS utilized in the treatment. Secondly, multivariate immune signaling, activation, and response may follow that may manifest as stimulatory, inhibitory, or both.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company believes that it is the first entity to advance an RBS formulation into clinical trials for the treatment of a disease, such as those trials reported on the clinical trials registry ClinicalTrials.gov.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company believes that it is the first and only entity to date to successfully, reproducibly, and consistently make pharmaceutical-grade RBS at a purity of nearly 100%. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company’s small molecule HX medical science platform comprises a number of different drug product candidates and preclinical pharmaceutical-grade RBS formulations using different concentrations and delivered by different routes of administration specific to each disease area and/or indication. The Company’s HX medical science platform includes clinical development programs in oncology, dermatology, and ophthalmology; proof-of-concept <i>in vivo</i> drug discovery programs in oncology, hematology, wound healing, and animal health; and preclinical <i>in vitro</i> drug discovery programs in infectious diseases and tissue regeneration and repair.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risks and Uncertainties</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s activities are subject to significant risks and uncertainties, including failing to successfully develop and license or commercialize the Company’s prescription drug candidates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Severe acute respiratory syndrome (“SARS”) coronavirus (“CoV”) 2 (“SARS-CoV-2”) was first identified in late-2019 and subsequently declared a global pandemic by the World Health Organization on March 11, 2020. As a result of the SARS-CoV-2 pandemic, many companies have experienced disruptions of their operations and the markets they serve. The Company has taken several temporary precautionary measures intended to help ensure the well-being of its employees and contractors and to minimize business disruption. The Company considered the impact of SARS-CoV-2 pandemic on its business and operational assumptions and estimates, and determined there were no material adverse impacts on the Company’s results of operations and financial position at September 30, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The full extent of the SARS-CoV-2 pandemic impacts on the Company’s operations and financial condition is uncertain. The Company has experienced slower than normal enrollment and treatment of patients, and a prolonged SARS-CoV-2 pandemic could have a material adverse impact on the Company’s business and financial results, including the timing and ability of the Company to raise capital, initiate and/or complete current and/or future preclinical studies and/or clinical trials, disrupt the Company’s regulatory activities, and/or have other adverse effects on the Company’s clinical development.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Basis of Presentation</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information pursuant to Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements and should be reviewed in conjunction with the Company’s audited consolidated financial statements included in the Company’s Form 10-K for the year ended December 31, 2021 filed with the SEC on March 29, 2022. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and nine months ended September 30, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1711351	usd
CY2022Q3	us-gaap	Restricted Cash RestrictedCash	1644321	usd
CY2022Q3	PVCT	Working Capital Deficiency WorkingCapitalDeficiency	6924589	usd
CY2021Q4	PVCT	Working Capital Deficiency WorkingCapitalDeficiency	4258679	usd
CY2022Q3	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2021Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	42594	usd
CY2021Q4	PVCT	Proceeds From Grant Award For Study Of Animal Cancer And Dermatological ProceedsFromGrantAwardForStudyOfAnimalCancerAndDermatological	2500000	usd
CY2021Q4	PVCT	Payment To Vendors For Expense And Deposits PaymentToVendorsForExpenseAndDeposits	855679	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_842_eus-gaap--ConcentrationRiskCreditRisk_zfVaAYdqIldk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_862_zUQtU3Z17f1">Cash Concentrations</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash, cash equivalents, and restricted cash are maintained at financial institutions and, at times, balances may exceed federally insured limits of $<span id="xdx_901_eus-gaap--CashFDICInsuredAmount_iI_c20220930_zOktQkTWZmfc" title="Insured limits">250,000</span>, although the Company seeks to minimize this through treasury management. The Company has never experienced any losses related to these balances although no assurance can be provided that it will not experience any losses in the future. As of September 30, 2022 and December 31, 2021, the Company had cash, cash equivalents, and restricted cash balances in excess of FDIC insurance limits of $<span id="xdx_90B_eus-gaap--FDICIndemnificationAsset_iI_c20220930_zuRRkBUwbUW" title="Cash in excess FDIC insured amount">1,461,351</span> and $<span id="xdx_90C_eus-gaap--FDICIndemnificationAsset_iI_c20211231_z5RyqiKQdF5h" title="Cash in excess FDIC insured amount">2,856,942</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q3	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2022Q3	us-gaap	Fdic Indemnification Asset FDICIndemnificationAsset	1461351	usd
CY2021Q4	us-gaap	Fdic Indemnification Asset FDICIndemnificationAsset	2856942	usd
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_841_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zwjTo9wZ9PJj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_861_zKvqQvaaGuve">Reclassifications</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain prior year balances have been reclassified in order to conform to current year presentation. These reclassifications had no effect on previously reported results of operations or loss per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	118243675	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	108695237	shares
CY2022Q3	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	300691	usd
CY2021Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	174533	usd
CY2022Q3	us-gaap	Accrued Vacation Current AccruedVacationCurrent	57088	usd
CY2021Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	42871	usd
CY2022Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1849339	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1560589	usd
CY2022Q3	PVCT	Accrued Other Expenses AccruedOtherExpenses	237106	usd
CY2021Q4	PVCT	Accrued Other Expenses AccruedOtherExpenses	224493	usd
CY2022Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2444224	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2002486	usd
CY2022Q3	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	3425000	shares
	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P2Y11M15D
CY2022Q3	us-gaap	Notes Payable NotesPayable	72135	usd
CY2021Q4	us-gaap	Notes Payable NotesPayable	238452	usd
CY2022Q3	us-gaap	Officers Compensation OfficersCompensation	96250	usd
CY2021Q3	us-gaap	Officers Compensation OfficersCompensation	96250	usd
	us-gaap	Officers Compensation OfficersCompensation	288750	usd
	us-gaap	Officers Compensation OfficersCompensation	288750	usd
CY2022Q3	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	1849339	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	1560589	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3625000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.32
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	200000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.86
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3425000	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.29
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	512500	shares
CY2021Q4	PVCT	Weighted Average Exercise Price Outstanding WeightedAverageExercisePriceOutstanding	0.92
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations	25000	shares
	PVCT	Weighted Average Exercise Price Forfeited WeightedAverageExercisePriceForfeited	0.29
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	487500	shares
CY2022Q3	PVCT	Weighted Average Exercise Price Outstanding WeightedAverageExercisePriceOutstanding	0.95
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	487500	shares
	PVCT	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Exercisable Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm2	P1Y6M
	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	to effect a reverse stock split of the Company’s common stock, Series D Convertible Preferred Stock, and Series D-1 Convertible Preferred Stock at a ratio of between 1-for-10 and 1-for-50
	us-gaap	Operating Lease Payments OperatingLeasePayments	50784	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	64231	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	130422	usd
CY2022Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y9M
CY2021Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P9M
CY2021Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.080	pure
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	12159	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	49311	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	50663	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	25669	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	137802	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	9406	usd
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	128396	usd
CY2021Q4	PVCT	Proceeds From Grant Award For Study Of Animal Cancer And Dermatological ProceedsFromGrantAwardForStudyOfAnimalCancerAndDermatological	2500000	usd
CY2022Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1675795	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	824205	usd
	PVCT	License Transaction Description LicenseTransactionDescription	the Company paid $5,000 for the option that expires on May 31, 2023, and agreed to pay up to $10,000 of new UM patent expenses for this IP during the period of the option and up to $25,000 of past UM patent expenses for this IP. The Company also entered into a sponsored research agreement with UM on September 16, 2022 to study the combination of OBC’s PDAT and TOP PV-305, a formulation of the Company’s pharmaceutical-grade RBS, for the treatment of infectious keratitis. This sponsored research by the Company is not associated with BPEI’s clinical efforts to utilize non-pharmaceutical grade rose bengal.

Files In Submission

Name	View Source	Status
0001493152-22-031108-index-headers.html	Edgar Link	pending
0001493152-22-031108-index.html	Edgar Link	pending
0001493152-22-031108.txt	Edgar Link	pending
0001493152-22-031108-xbrl.zip	Edgar Link	pending
ex10-1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pvct-20220930.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
pvct-20220930_cal.xml	Edgar Link	unprocessable
pvct-20220930_def.xml	Edgar Link	unprocessable
pvct-20220930_lab.xml	Edgar Link	unprocessable
pvct-20220930_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PVCT
PROVECTUS BIOPHARMACEUTICALS, INC. Stock $pvct

2022 Q4 Form 10-Q Financial Statement

#000149315222031108 Filed on November 09, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PVCT PROVECTUS BIOPHARMACEUTICALS, INC. Stock $pvct

2022 Q4 Form 10-Q Financial Statement

#000149315222031108 Filed on November 09, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PVCT
PROVECTUS BIOPHARMACEUTICALS, INC. Stock $pvct